Risk of developing antiphospholipid antibodies following viral infection: a systematic review and meta-analysis

Lupus - Tập 27 Số 4 - Trang 572-583 - 2018
Noha Abdel‐Wahab1,2, Saurabh Talathi3, María A. López-Olivo2, María E. Suárez-Almazor2
1Rheumatology and Rehabilitation Department, Assiut University Hospitals, Faculty of Medicine, Assiut, Egypt
2Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
3Lincoln Medical Center, Weill Cornell Medical College, Bronx, NY, USA

Tóm tắt

Objective The objective of this paper is to conduct a systematic review and meta-analysis on the risk of developing elevated antiphospholipid (aPL) antibodies and related thromboembolic and/or pregnancy events following a viral infection. Method We searched Medline, EMBASE, Web of Science, PubMed ePubs, and Cochrane Central Register of Controlled Trials through June 2016. Independent observational studies of elevated aPL antibodies in patients with a viral infection compared with controls or patients with lupus were included. Results We analyzed 73 publications for 60 studies. Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) were most commonly reported. Compared with healthy controls, patients with HIV were more likely to develop elevated anticardiolipin (aCL) antibodies (risk ratio (RR) 10.5, 95% confidence interval (CI) 5.6–19.4), as were those with HCV (RR 6.3, 95% CI 3.9–10.1), hepatitis B virus (HBV) (RR 4.2, 95% CI 1.8–9.5), and Epstein-Barr virus (EBV) (RR 10.9 95% CI 5.4–22.2). The only statistically significant increased risk for anti-β2-glycoprotein I (anti-β2-GPI) antibodies was observed in patients with HCV (RR 4.8 95% CI 1.0–22.3). Compared with patients with lupus, patients with HIV were more likely to develop elevated aCL antibodies (RR 1.8, 95% CI 1.3–2.6), and those with EBV, elevated anti-β2-GPI antibodies (RR 2.2, 95% CI 1.3–3.9). Thromboembolic events were most prevalent in patients with elevated aPL antibodies who had HCV (9.1%, 95% CI 3.0–18.1), and HBV (5.9%, 95% CI 2.0–11.9) infections, and pregnancy events were most prevalent in those with parvovirus B19 (16.3%, 95% CI 0.78–45.7). However, compared to virus-infected patients with negative aPL antibodies, the only statistically significant increased risk was observed in those with HCV and positive aPL. Conclusions Viral infection can increase the risk of developing elevated aPL antibodies and associated thromboembolic events. Results are contingent on the reported information.

Từ khóa


Tài liệu tham khảo

Juby AG, 1998, Clin Invest Med, 21, 4

10.1056/NEJMra002974

Mchrani T, 2009, Handbook of systemic autoimmune diseases, 13

10.1006/jaut.2000.0409

10.1111/j.1445-5994.1990.tb01025.x

10.1111/j.1538-7836.2006.01753.x

10.1002/art.10187

10.1111/1756-185X.12438

10.1136/ard.2005.045443

10.1177/0961203316640912

Wells GA, Shea B, O’Connell D, et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses, http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed 5 August 2017).

The Nordic Cochrane Center TCC, 2014, Copenhagen, Denmark, http://community.cochrane.org/tools/review-production-tools/revman-5/revman-5-download (accessed 5 August 2017).

StataCorp. Stata Statistical Software: Release 11. StataCorp LP; College Station, TX.

10.1136/bmj.315.7109.629

10.1136/bmj.d4002

Blank A, 1995, J Acquir Immune Defic Syndr Hum Retrovirol, 10, 80

10.1191/096120399678847731

Medina-Rodriguez F, 1993, J Rheumatol, 20, 1880

10.1177/107602969800400311

10.1002/pd.1970151205

10.1089/108729101753205685

Abuaf N, 1997, Thromb Haemost, 77, 856, 10.1055/s-0038-1656067

10.1016/S0022-2143(98)90096-8

10.5045/kjh.2011.46.1.36

10.1002/jcla.10093

Johnstone FD, 1992, Obstet Gynecol, 80, 92

10.1097/00042737-200012010-00013

Di Prima MA, 1988, Medicina (Firenze), 8, 423

10.1046/j.1365-2141.1998.00722.x

10.1111/j.1572-0241.1999.01447.x

Masala C, 1991, EOS, 11, 109

Matsuda J, 1995, Am J Gastroenterol, 90, 1138

10.1097/00042560-200108150-00015

10.1002/hep.510230201

10.1046/j.8755-8920.2003.00105.x

10.1007/s005350050345

Toyoshima M, 2012, Dev Med Child Neurol, 54, 176, 10.1111/j.1469-8749.2011.04160.x

10.1111/j.1365-2249.2005.02727.x

10.1046/j.1365-2362.2003.01110.x

10.1590/S0100-879X2008005000024

10.1046/j.1365-2362.1998.00254.x

10.1016/j.inmuno.2012.10.002

10.1001/archinte.1989.00390080091020

Canoso RT, 1986, Clin Res, 34, A453

10.1111/j.1365-2141.1987.tb04157.x

10.1046/j.1365-2249.1997.4601357.x

10.1016/j.autrev.2007.10.001

10.1016/j.dld.2015.03.006

10.3181/00379727-48-13365P

Michaelis L, 1907, Berl Klin Wochenschr, 44, 1635

10.1055/s-0028-1142018

Landsteiner K, 1907, Wien Klin Wochenschr, 20, 1565

10.1001/jama.1941.02820340013005

10.1001/jama.1952.03680050033010

Harvey AM, 1974, Lupus erythematosus. 4th ed, 196

Koike T, 1984, Clin Exp Immunol, 56, 193

10.1016/0021-9681(55)90039-4

Hughes GR, 1986, J Rheumatol, 13, 486

10.1016/0140-6736(90)91374-J

10.1016/0140-6736(90)91697-9

10.1084/jem.179.2.457

10.1073/pnas.87.11.4120

Gharavi AE, 1994, J Rheumatol, 21, 94

10.1177/096120339200100204

10.1172/JCI115926

10.1002/art.1780400115

10.1111/jth.13320

Barrile A, 1992, Recenti Prog Med, 83, 350

Carreño L, 1994, J Rheumatol, 21, 1344

Chretien P, 2003, Clin Exp Rheumatol, 21, 210

10.1007/BF01704601

Deril GM, 1995, Clin Chem, 41, S100

González Domínguez J, 1995, Rev Clin Esp (Barc), 195, 8

10.1111/j.1365-2249.1990.tb03328.x

10.1097/00002030-199715000-00009

10.1007/BF00916816

10.1006/jaut.1999.0324

10.1016/0090-1229(95)90138-8

10.1016/0049-3848(94)90095-7

Agarwal N, 2001, Indian J Med Res, 113, 170

Cacoub P, 1997, J Rheumatol, 24, 2139

Guerrero FJ, 1998, Med Clin (Barc), 110, 319

10.1002/jcla.21529

Nagao Y, 2002, Int J Mol Med, 9, 293

Ordi-Ros J, 2000, Clin Diagn Lab Immunol, 7, 241, 10.1128/CDLI.7.2.241-244.2000

Romero Gómez M, 2000, Med Clin (Barc), 114, 367, 10.1016/S0025-7753(00)71299-1

Salazar LA, 2010, Hepat Res Treat, 2010, 971095

10.1136/ard.59.6.483

10.1016/j.clim.2006.01.002

10.1111/j.1365-2249.1993.tb05950.x

10.1097/01.meg.0000059140.68845.74

Dostál C, 1990, J Rheumatol, 17, 1573

10.1046/j.1365-2249.2000.01206.x

Elías Calvo CJ, 1993, Med Clin (Barc), 100, 797

Ndakotsu MA, 2009, J Microbiol Immunol Infect, 42, 69

Caporali R, 1988, Med Sci Res, 16, 537

10.3109/08916939908994054

10.1016/S0248-8663(05)80454-0

Adebajo AO, 1992, Br J Rheumatol, 31, 45, 10.1093/rheumatology/31.4.275

Biron C, 1996, Ann Med Interne (Paris), 147, 48

Coll J, 1993, Med Clin (Barc), 100, 357

Dostál C, 1990, Vnitr Lek, 36, 1050

10.1016/S0016-5085(00)85920-X

Hunt JE, 1991, FASEB J, 5, A1088

10.1016/S0168-8278(00)80722-9

10.1007/s10875-008-9211-6

10.1016/j.jaut.2005.01.016

10.1016/S0168-8278(02)80498-6

Thông tin
Thông tin xuất bản

Lupus

Tập 27 Số 4

572-583

Thông tin tác giả